Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacy Compounding Could Be Added To PDUFA III, APhA’s Winckler Says

Executive Summary

Pharmacy compounding could be revisited in the Prescription Drug User Fee Act if there is a Supreme Court decision before reauthorization is finalized, American Pharmaceutical Association Policy & Advocacy Group Director Susan Winckler said

You may also be interested in...

NACDS Interim Medicare Rx Plan: “OneCard” Plus Stop-Loss Coverage

The National Association of Chain Drug Stores is pushing its "OneCard" program as part of a two-prong interim legislative solution to help seniors afford prescription drugs in the absence of a Medicare Rx benefit

FDA Rx Compounding Ad Restrictions May Be Unnecessary, Justices Say

FDA restrictions on advertising compounded drugs may not be justified given the additional safeguards provided under the FDA Modernization Act, U.S. Supreme Court justices suggested during oral arguments in Thompson v. Western States Medical Center Feb. 26

Pharmacy Groups Exploring Medicare Rx Fallback Options

The retail pharmacy trade associations hope to reach an agreement on a fallback Medicare drug benefit proposal with a group of pharmaceutical manufacturers over the next month




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts